

① ROVO 01
54 Pages

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, G01N 33/574		(11) International Publication Number: WO 98/05797
A1		(43) International Publication Date: 12 February 1998 (12.02.98)
(21) International Application Number: PCT US97 13888		(74) Agents: POLIZZI, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).
(22) International Filing Date: 6 August 1997 (06.08.97)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(30) Priority Data: 08.692.759 6 August 1996 (06.08.96) US Not furnished 4 August 1997 (04.08.97) US		Published With international search report With amended claims Date of publication of the amended claims: 14 May 1998 (14.05.98)
(60) Parent Application or Grant (63) Related by Continuation US Not furnished (CON) Filed on 4 August 1997 (04.08.97)		
(71) Applicant (for all designated States except US): CALYDON [US/US]; 1014 Hamilton Court, Menlo Park, CA 94025 (US).		
(72) Inventors; and (75) Inventors/Applicants (for US only): HENDERSON, Daniel, R. [US/US]; 955 Matadero Avenue, Palo Alto, CA 94306 (US). SCHUUR, Eric, R. [US/US]; 20350 Stevens Creek Boulevard #305, Cupertino, CA 95014 (US). LAMPARSKI, Henry, G. [CA/US]; 422 South El Dorado, San Mateo, CA 94402 (US). YU, De-Chao [CN/US]; 1046 Eagle Lane, Foster City, CA 94404 (US).		
(54) Title: PROSTATE CANCER DRUG SCREENING		
(57) Abstract Screening of compounds for activity toward inhibition of prostate cancer cell proliferation is provided. A cell line is employed which can be used in conventional equipment for determining activity of compounds, where the cell line uses a marker whose expression is responsive to therapeutically active compounds.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	JS	Josotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NF	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

[received by the International Bureau on 14 March 1998 (14 03.98);
original claims 8-18 amended; new claims 19-25 added; remaining claims unchanged (3 pages)]

combining said PSA expressing cells with a candidate drug in the presence of
methyl trienolone or dihydrotestosterone for sufficient time for detectable expression of
said enzyme;

lysing said PSA expressing cells to provide a lysate and adding the substrate of said
enzyme to said lysate; and

detecting the level of expression of said enzyme as compared to the level of
expression in the absence of said candidate drug.

7. A method according to Claim 6, wherein said PSA expressing cells are
LNCaP cells and said enzyme is luciferase.

8. A method according to claims 1 or 6, wherein the prostate specific antigen
enhancer comprises a sequence encompassing nucleotides between about -5824 to about -
3738 of the upstream region of the PSA gene, wherein the enhancer exhibits enhancer
activity.

9. A method according to claims 1 or 6, wherein the prostate specific antigen
enhancer is contained within a polynucleotide fragment of about 5.8 kilobases from about -
5824 to about +1 of the upstream region of the PSA gene, wherein the enhancer exhibits
enhancer activity.

10. A method according to claim 10, wherein the promoter comprises a sequence
encompassing nucleotides between about -560 to about +7 of the PSA gene.

11. A method for screening compounds for the treatment of prostate cancer
employing cells comprising an expression construct, said expression construct comprising
an enhancer of a prostate-specific gene and a promoter and a reporter gene whose
expression product provides a detectable signal, wherein said reporter gene is under the
transcriptional control of said enhancer, said method comprising the steps of:

- a) combining said cells with a candidate compound for a sufficient time for
detectable expression of said reporter gene; and
- b) detecting the level of expression of said reporter gene as compared to the level
of expression in the absence of said candidate compound.

12. A method according to claim 11, wherein said reporter gene expresses an enzyme.

13. A method according to claim 12, wherein said enzyme is luciferase.

14. A method according to claim 13, wherein said detecting comprises: lysing said cells; and assaying said lysate for luminescence.

15. A method according to claim 11, wherein said enhancer is an enhancer region of the human prostate specific antigen (PSA) gene.

16. A method according to claim 15, wherein the prostate specific antigen enhancer comprises a sequence encompassing nucleotides between about -5824 to about -3738 of the upstream region of the PSA gene, wherein the enhancer exhibits enhancer activity.

17. A method according to claim 11, wherein said enhancer from the human glandular kallikrein (*hKLK2*) gene.

18. A method according to claim 17, wherein the *hKLK2* enhancer comprises a sequence encompassing nucleotides about 1 to about 9765 of SEQ ID NO:1 or active fragments thereof.

19. A method according to claim 17, wherein the *hKLK2* enhancer comprises a sequence encompassing nucleotides about 5976 to about 9620 of SEQ ID NO:1 or active fragments thereof.

20. A method according to claim 17, wherein the *hKLK2* enhancer comprises a sequence encompassing nucleotides about 6859 to about 8627 of SEQ ID NO:1 or active fragments thereof.

21. A method of any of claims 17 to 20, wherein the promoter is an *hKLK2* promoter.

22. A method of any of claims 11 to 21, wherein the cells are mammalian.

23. A method of claim 22, wherein the mammalian cells express prostate specific antigen.

5 24. A method of claim 22 or 23, wherein the cells are prostate.

25. A method of claim 24, wherein the prostate cells contain an endogenous androgen receptor.

CORRECTED
VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, G01N 33/574		A1	(11) International Publication Number: WO 98/05797
			(43) International Publication Date: 12 February 1998 (12.02.98)
(21) International Application Number: PCT/US97/13888		(74) Agents: POLIZZIO, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).	
(22) International Filing Date: 6 August 1997 (06.08.97)			
(30) Priority Data: 08 692,759 6 August 1996 (06.08.96) US Not furnished 4 August 1997 (04.08.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US Not furnished (CON) Filed on 4 August 1997 (04.08.97)		Published With international search report With amended claims	
(71) Applicant (for all designated states except US): CALYDON [US, US]: 1014 Hamilton Court, Menlo Park, CA 94025 (US).		Date of publication of the amended claims: 14 May 1998 (14.05.98)	
(72) Inventors; and (75) Inventors/Applicants (for US only): HENDERSON, Daniel, R. [US, US]; 955 Matadero Avenue, Palo Alto, CA 94306 (US); SCHUUR, Eric, R. [US, US]; 20350 Stevens Creek Boulevard #305, Cupertino, CA 95014 (US); LAMPARSKI, Henry, G. [CA, US]; 422 South El Dorado, San Mateo, CA 94402 (US); YU, De-Chao [CN, US]; 1046 Eagle Lane, Foster City, CA 94404 (US)			
(54) Title: PROSTATE CANCER DRUG SCREENING			
(57) Abstract Screening of compounds for activity toward inhibition of prostate cancer cell proliferation is provided. A cell line is employed which can be used in conventional equipment for determining activity of compounds, where the cell line uses a marker whose expression is responsive to therapeutically active compounds.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROSTATE CANCER DRUG SCREENING

TECHNICAL FIELD

5 The present invention relates to screening methods for identifying compounds useful in the treatment of prostate cancer.

BACKGROUND

10 Prostate cancer is the fastest growing neoplasm in men with an estimated 244,000 new cases in the United States being diagnosed in 1995, of which approximately 44,000 deaths will result. Hormonal ablation therapy, either surgically or chemically with anti-androgens, is the main stay of treatment for advanced carcinoma of the prostate. However, androgen ablation therapy failed within 12-18 months with the disease becoming androgen independent. Following the failure of androgen therapy, the median patient survival time is eight months.
5 Other approaches to treating prostate cancer -- external radiation, radioactive seed therapy, cryotherapy, etc.-- are directed toward organ confined disease of the prostate and are unable to treat metastatic tumors.

The prostate-specific antigen (PSA), a member of the human kallikrein gene family, is a Mr = 34,000 chymotrypsin like protein that is synthesized exclusively by normal,
10 hyperplastic, and malignant prostatic epithelia. Hence, the PSA's tissue-specific relationship has made it an excellent biomarker for identifying benign prostatic hyperplasia (BPH) and prostatic carcinoma (CaP), hereinafter CaP. Normal serum levels of PSA in blood are typically below 5 ng/ml, with elevated levels indicative of BPH or CaP. Serum levels of 200 ng/ml have been measured in end-stage metastatic CaP.

15 Another member of the kallikrein gene family, human glandular kallikrein-1 (*hGK-1* or *hK2*, encoding the hK2 protein), shares a number of characteristics with PSA. First, both are expressed exclusively in the prostate and are up-regulated by androgens primarily by

transcriptional activation. Wolf et al. (1992) *Molec. Endocrinol.* 6:753-762. Morris (1989) *Clin. Exp. Pharm. Physiol.* 16:345-351; Qui et al. (1990) *J. Urol.* 144:1550-1556; Young et al. (1992) *Biochem.* 31:818-824. Second, *hKLK2* and *PSA* mRNAs are synthesized and co-localize only in prostatic epithelia. Third, *hKLK2* and *PSA* exhibit a high degree of amino acid sequence identity. Schedlich et al. (1987) *DNA* 6:429-437. Fourth, they have similar regulatory elements. There is approximately 80% nucleotide sequence identity between *PSA* and *hKLK2* in the 5'-flanking region from -300 to -1 relative to the transcription initiation site. Young et al. (1992) *Biochem.* 31:818-824. Each promoter contains an androgen responsive element (ARE); their respective ARE's differ from one another by only 1 nucleotide. Schedlich et al. (1987) *DNA* 6:429-437; Murtha et al. (1993) *Biochem.* 32:6459-6464.

The levels of hK2 found in various tumors and in the serum of patients with prostate cancer differ substantially from those of PSA. Circulating hK2 in different relative proportions to PSA has been detected in the serum of patients with prostate cancer. Charlesworth et al. (1997) *Urology* 49:487-493. Expression of hK2 has been detected in each of 257 radical prostatectomy specimens analyzed. Darson et al. (1997) *Urology* 49:857-862. The intensity and extent of hK2 expression, detected using specific antibodies, increased from benign epithelium to high-grade prostatic intraepithelial neoplasia (PIN) and adenocarcinoma, whereas PSA and prostatic acid phosphatase (PAP) displayed an inverse pattern of immunoreactivity. Darson et al. (1997) *Urology* 49:857-862. Indeed, it has been reported that a certain percentage of PSA-negative tumors have detectable hK2. Tremblay et al. (1997) *Am. J. Pathol.* 150:455-459.

As mentioned above, both *PSA* and *hKLK2* genes are up-regulated by androgens primarily by transcriptional activation. Androgen induction of gene expression requires the presence of an androgen receptor (AR). Typically, an androgen diffuses passively into the cell where it binds AR. The androgen-activated AR binds to specific DNA sequences called androgen-responsive elements (AREs or ARE sites). Once anchored to an ARE, the AR is able to regulate transcriptional activity in either a positive or negative fashion. Lindzey et al. (1994) *Vitamins and Hormones* 49: 383-432.

The AR belongs to a nuclear receptor superfamily whose members are believed to function primarily as transcription factors that regulate gene activity through binding to specific DNA sequences, hormone-responsive elements. Carson-Jurica et al. (1990) *Endocr. Rev.* 11: 201-220. This family includes the other steroid hormone receptors as well as the thyroid hormone, the retinoic acid and the vitamin D₃ receptors. The progesterone and glucocorticoid receptor are structurally most closely related to the AR. Tilley et al. (1989) *Proc. Natl. Acad. Sci. USA* 86: 327-331; Zhou et al. (1994) *Recent Prog. Horm. Res.* 49: 249-274; and Lindzey et al. (1994) *Vit. Horm.* 49: 383-432.

The AR gene itself is a target of androgenic regulation. In the prostate cancer cells lines PC3 and DU145, which do not express an endogenous AR, androgenic up-regulation of AR cDNA expression occurred in the transfected cells. Dai et al. (1996). Androgenic up-regulation of AR mRNA and protein was observed in PC3 cells that were stably transfected with the AR cDNA, suggesting that AR mRNA regulation also occurs when the cDNA is organized into chromatin. Dai et al. (1996).

The characterization of genes whose expression is limited to the prostate allows the development of screening methods which can identify substances capable of specifically altering the expression of prostate-specific genes.

In the last few years, numerous techniques have been developed for producing vast arrays of potential drug-like compounds. These compounds include not only oligomers, such as oligopeptides and oligonucleotides, but also synthetic organic compounds based on various core structures. In addition, various natural sources have been screened for active compounds, such as those found in jungles, the ocean and the like. Thus, there is a great proliferation of available compounds for screening for physiological activity.

The process of identifying prospective compounds having therapeutic activity is primarily held back by the absence of useful screening assays. In order for a screening assay to be useful, it should be capable of automation, allow for the screening of large numbers of samples without requiring extensive equipment or housing, be relatively inexpensive, and provide for a clear indication of activity. There is, therefore, substantial interest in identifying

new screening assays which would allow for the screening of compounds which may have therapeutic activity in relation to prostate cancer.

SUMMARY OF THE INVENTION

5 Methods and compositions are provided for screening therapeutic agents for the treatment of prostate cancer. The methods employ a PSA expressing stably transformed epithelial cell line comprising a construct of the PSA gene enhancer/promoter and a marker gene, e.g. luciferase. The cells are shown to be responsive to the addition of androgen agonists and antagonists by the modified expression of the marker gene. The methods also
10 employ a cell line derived from the prostate, which cell line is stably transformed with a construct comprising a transcriptional control region of a gene, such as PSA or *hKLK2*, whose expression is substantially limited to cells of the prostate, and a reporter gene. Alterations in the levels of reporter gene product in the presence of a candidate agent or compound are indicative of a potential therapeutic agent.

15 Accordingly, in one aspect, the invention includes a method for screening drugs for the treatment of prostate cancer employing PSA expressing cells comprising an expression construct which comprises a transcriptional initiation region of the prostate specific antigen enhancer and a promoter and a gene whose expression product provides a detectable signal, wherein said gene is under the transcriptional control of said transcriptional initiation region.
20 said method comprising combining said PSA expressing cells with a candidate drug in the presence of an androgen for sufficient time for detectable expression of said gene, and detecting the level of expression of said gene as compared to the level of expression in the absence of said candidate drug.

25 In another aspect, the invention provides a method A method for screening drugs for the treatment of prostate cancer employing PSA expressing cells comprising an expression construct which comprises a transcriptional initiation region of the prostate specific antigen enhancer and a promoter and a gene encoding an enzyme which catalyzes a reaction resulting, in a detectable signal, wherein said gene is under the transcriptional control of said transcriptional initiation region, said method comprising combining said PSA expressing cells

with a candidate drug in the presence of methyl trienolone or dihydrotestosterone for sufficient time for detectable expression of said enzyme, lysing said PSA expressing cells to provide a lysate and adding the substrate of said enzyme to said lysate, and detecting the level of expression of said enzyme as compared to the level of expression in the absence of said candidate drug.

In another aspect, the invention provides a method for screening compounds for the treatment of prostate cancer employing mammalian cells comprising an expression construct, said expression construct comprising an enhancer of a prostate-specific gene and a promoter and a reporter gene whose expression product provides a detectable signal, wherein said reporter gene is under the transcriptional control of said enhancer, said method comprising the steps of combining said cells with a candidate compound for a sufficient time for detectable expression of said reporter gene, and detecting the level of expression of said reporter gene as compared to the level of expression in the absence of said candidate compound.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a bar graph of anti-androgen induction/inhibition on luciferase expression by the cell line CN1013. Figure 1A indicating induction by hydroxyflutamide, and Figure 1B by cyproterone acetate, before (white bars) and after (dark bars) induction with 1 nM R1881.

Figure 2 is a schematic representation of the hK2 promoter/enhancer region (SEQ ID NO:1). The hatched bar represents the promoter region (Schedlich et al. (1987); GenBank accession number M18156); the dotted portion (including the solid portion) represents an enhancer region; the solid portion represents a smaller region with enhancer activity; and the transcription initiation site is indicated by a bent arrow.

Figures 3A and 3B are bar graphs of testosterone analog R1881 induction of *hKLK2* promoter/enhancer-driven luciferase expression in LNCaP (human metastatic prostate adenocarcinoma) cells. LNCaP cells were transfected with reporter gene constructs, incubated in the presence or absence of inducer, and, 48 hours after transfection, luciferase activity was measured. Figure 3A shows induction, expressed in relative light units (RLU) per μg total protein, of luciferase expression by the *hKLK2* promoter-containing construct CN299

(stippled bars) or by the *hKLK2* promoter/enhancer-containing construct CN322 (solid bars) in the presence of 0 nM or 0.5 nM R1881. Figure 3B shows the fold induction calculated by comparing CN322 RLU/ μ g protein with CN299 RLU/ μ g protein in the presence of 0.5 nM R1881.

Figures 4A and 4B are bar graphs of the concentration dependence of R1881-mediated induction of *hKLK2* promoter/enhancer-driven luciferase expression. LNCaP cells were transfected with CN322 and cells were incubated in various concentrations of R1881. Cells were harvested 48 hours after transfection and luciferase activity was measured. Figure 4A shows luciferase activity, expressed as RLU/ μ g protein, from cultures incubated in the presence of 0, 0.01, 0.1, 1, or 10 nM R1881. Figure 4B shows fold induction calculated by comparing RLU/ μ g protein at a given concentration to RLU/ μ g protein at 0 nM R1881.

Figure 5 is a bar graph showing induction of luciferase activity as a function of time of incubation with R1881. LNCaP cells were transfected with CN322 and cells were incubated in medium containing 0.5 nM R1881 for various periods of time, after which luciferase activity was measured.

Figure 6 is a bar graph depicting the cell type specificity of *hKLK2* promoter/enhancer-driven luciferase expression. LNCaP or 293 (human embryonal kidney) cells were transfected with CN299 or with CN322 plasmid constructs and incubated in the absence or the presence of 1 nM R1881. Cells were harvested 48 hours post transfection and luciferase activity was measured. Fold induction was calculated by comparing RLU/ μ g protein with and without 1 nM R1881.

Figure 7 is a bar graph depicting the activity of the *hKLK2* enhancer/promoter in various cell lines. Various cell lines were transfected with either CN322 or CN355, and, after an overnight incubation in complete medium, were incubated in the presence or absence of R1881. CN355 contains a 3.8 kb fragment from approximately -6200 to approximately -2400 of the *hKLK2* enhancer fused to the minimal *hKLK2* promoter to control luciferase expression. The cell lines used were: OVCAR, human ovarian adenocarcinoma; 293, transformed human primary embryonal kidney; PC3, human grade IV prostate adenocarcinoma; LNCaP, metastatic human prostate adenocarcinoma.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Methods are provided for screening compounds for therapeutic effect against prostate cancer. The methods comprise adding the compound in an appropriate medium to PSA
5 producing cells into which has been stably introduced a genetic construct comprising the enhancer promoter of the prostate-specific antigen (PSA) with a structural gene under the transcriptional regulation of the PSA enhancer promoter.

Alternatively, the methods comprise adding the compound in an appropriate medium to cells, preferably derived from the prostate, into which has been stably introduced a genetic
10 construct comprising a transcriptional control region of a prostate-specific gene with a structural gene under the transcriptional regulation of the prostate-specific gene transcriptional control region, which structural gene provides for a detectable, quantifiable signal. Examples of prostate-specific genes include, but are not limited to, PSA and *hKLK2*. By measuring the effect of the candidate compound on the level of signal observed as compared to a basal level,
5 one can evaluate the potential of the compound as a therapeutic agent for the treatment of prostate cancer. Particularly, anti-androgenic activity can be evaluated as indicative of therapeutic effects for prostate cancer, although any compound which modifies the expression of a prostate-specific gene, whatever its mode of action, may be considered a candidate compound.

Cells which are suitable for use in the screening methods of the present invention are mammalian cells in which at least one prostate-specific gene is expressed in the cells.
10 Preferably, the cells are prostate cells, more preferably expressing endogenous androgen receptor, even more preferably prostate epithelial cells expressing endogenous androgen receptor. Preferably, the cells employed display expression of the prostate-specific gene whose transcriptional control region, in whole or in part, is contained within the construct used
15 to stably transform the cells. Alternatively, the cells need not be derived from the prostate as long as the normal function of the transcription regulatory elements of the prostate-specific gene is maintained. This may be achieved, for example, by co-transfecting the cell with a gene encoding a product necessary for the normal function of the promoter/enhancer region of

the prostate-specific gene. For example, if the promoter enhancer region of the prostate-specific gene is inducible by androgen, it may be necessary to co-transfect into the cells a construct which encodes and allows expression of a gene encoding an androgen receptor.

5 "Androgen receptor" as used herein refers to a protein whose function is to specifically bind to androgen and, as a consequence of the specific binding, recognize and bind to an androgen response element (ARE), following which the AR is capable of regulating transcriptional activity. The AR is a nuclear receptor that, when activated, binds to cellular androgen-responsive element(s). In normal cells the AR is activated by androgen, but in non-normal cells (including malignant cells) the AR may be activated by non-androgenic agents, including hormones. Encompassed in the term "androgen receptor" are mutant forms of an
10 androgen receptor, as long as the function is sufficiently preserved. Mutants include androgen receptors with amino acid additions, insertions, truncations and deletions, as long as the function is sufficiently preserved.

15 The term "prostate-specific gene" as used herein indicates a gene whose expression is substantially limited to cells of the prostate, in particular to prostate epithelial cells, and whose expression is substantially undetectable in normal cells derived from tissues other than the prostate.

20 The term "transcriptional control region" as used herein encompasses enhancers, promoter elements and/or any other nucleotide sequence which controls the level of transcription of a coding region.

25 The prostate-specific gene whose transcription control region is operably linked with a reporter gene may or may not be one whose expression in prostate cells or cell derived from the prostate is inducible, but preferably is inducible. The term "inducible gene" is used herein to indicate a gene which is normally transcriptionally silent in prostate cells or whose expression is substantially undetectable, and whose expression, in the presence of an appropriate inducing agent, is increased at least 10-fold, more preferably at least about 10- to about 50- fold, even more preferably about 50- to about 200-fold, relative to expression in the absence of the inducing agent.

An inducing agent can be any compound which is added to the growth environment of the cell and which, upon contact with and or entry into the cell, results in the expression of a specific gene or set of genes. For the purposes of the present invention, an "appropriate inducing agent" is one which specifically induces the expression of a gene which is operably
5 linked to a reporter gene. For example, both PSA and *hKLK2* enhancers are inducible with androgen. An example of an inducing agent used is R1881, a testosterone analog.

In one embodiment, the cells which are employed in the screening are stable prostate cancer cell lines which express PSA, particularly based on the LNCaP cell line, which are cells derived from a metastatic tumor isolated from a lymph node. This cell line has been
10 established for an extended period of time, stably maintains expression of PSA, and is readily grown in conventional media.

In this embodiment, the subject cells are produced by introducing an expression construct into a stable prostate cancer cell line expressing PSA at least a level of 10 to 20 ng/mL per 10^6 cells per day. The expression construct comprises as the transcriptional
15 initiation regulatory region, the PSA enhancer with the PSA promoter or a different promoter region, usually the PSA promoter. The 5' non-coding region of the PSA gene may include the region from 0 (the site of transcription initiation) to -6000 or may be truncated, to provide only those sequences essential for the enhancer region and the promoter region. Thus, the particular regions include the enhancer active sequences between -5824 and -3738 with the
20 promoter active region, for the PSA gene, the region from about -560 to +7.

In another embodiment, the cells employed are mammalian cells (preferably prostate cells, even more preferably LNCaP cells) and the expression construct comprises, as the transcriptional initiation regulatory region, an *hK2* enhancer with a promoter which may be an
25 *hK2* promoter or a heterologous promoter. The 5' non-coding region of the *hK2* gene may include the region from -33 (relative to the site of transcription initiation) to -12,014 or may be truncated to provide only those sequences essential for enhancer function and/or promoter function. Particular regions include an approximately 1.7 kb enhancer active fragment from -5155 to -3387 relative to the transcription start site (nucleotides 6859 to 8627 of SEQ ID NO:1), with the promoter active region being the region from about -600 to about

-33 relative to the transcription start site (from about 11420 to 12047 of SEQ ID NO:1). The DNA sequence as such can vary in length and or nucleotide sequence as long as the requisite function is maintained.

This transcription initiation regulatory region may then be joined to a marker gene which provides for a detectable, desirably quantifiable, signal. Of particular interest are genes which provide for luminescence, such as luciferase, aequorin, β -galactosidase, chloramphenicol acetyl transferase, etc. In addition, one may provide for a marker for selection comprising a constitutive transcriptional initiation region and an antibiotic resistance gene, e.g. neo. In this way, one may select for those cells which have the expression construct stably integrated.

Marker genes, or reporter genes, which may be employed are known to those skilled in the art and include, but are not limited to, luciferase; aequorin (i.e., green fluorescent protein from *Aequorea victoria*); β -galactosidase; chloramphenicol acetyl transferase; immunologically detectable protein "tags" such as human growth hormone; and the like. See, for example, Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987) and periodic updates. Any assay which detects a product of the reporter gene, either by directly detecting the protein encoded by the reporter gene or by detecting an enzymatic product of a reporter gene-encoded enzyme, is suitable for use in the present invention. Assays include colorimetric, fluorimetric, or luminescent assays or even, in the case of protein tags, radioimmunoassays or other immunological assays. Many of these assays are commercially available.

The construct may be prepared in accordance with conventional ways, introducing each of the components of the construct into a plasmid by employing convenient restriction sites, PCR (polymerase chain reaction) to introduce specific sequences at the termini, which may include providing for restriction sites, and the like. After the expression construct has been prepared, it may be introduced into the cells by any convenient means.

Methods for introducing the expression construct into the cells or cell lines include transfection, complexing with cationic compounds, lipofection, electroporation, and the like. The cells may be expanded and then screened for the presence of the expression construct.

Where an antibiotic resistance gene has been introduced, the cells may be selected for antibiotic resistance and the antibiotic resistance cells then screened for luminescence under appropriate conditions. In the absence of the antibiotic resistance, the cells may be directly screened for luminescence. Conveniently, the assay for luminescence is performed on a lysate
5 using conventional reagents.

After selecting clones which demonstrate high levels of luciferase activity when activated, the induction ratio may be further enhanced by performing limiting dilution with the cells and screening the resulting clones. In this manner, the induction may be at least 20 fold when induced with an inducing agent such as 0.1 - 1.0 nM R1881, preferably at least about 50
10 fold, and more preferably at least about 100 fold. Usually, the induction will not exceed about 500 fold.

When the prostate-specific gene used to transform the cell is hormone-inducible, cells are desirably grown in hormone-free medium, e.g. RPMI medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 µg/ml streptomycin, and assayed in
15 hormone spiked medium, e.g. 10% strip-serum RPMI with hormone. Desirably, the cells should not have been passaged more than about 50 times, more desirably not more than about 25 times.

The luminescence may be determined in accordance with conventional commercial kits, e.g. enhanced luciferase assay kit (Analytical Luminescence Laboratory, MI). The cells
20 may be distributed in multiwell plates which can be accommodated by a luminometer. A known number of cells is introduced into each one of the wells in an appropriate medium, the candidate compound added, and the culture maintained for at least 12 hours, more usually at least about 24, and not more than about 60 hours, particularly about 48 hours. The culture is then lysed in an appropriate buffer, using a non-ionic detergent, e.g. 1% triton X-100. The
25 cells are then promptly assayed. In conjunction with the candidate compound, an inducing compound, e.g. androgens, will also be added such as methyl trienolene (R1881), or dihydrotestosterone (DHT). The concentration of these inducing agents will vary depending upon the nature of the agent, but will be sufficient to induce expression. The concentration with R1881 will generally be in the range of about 0.1 - 10 nM, preferably about 1 nM.

Any other technique for detecting the level of luminescence may be used. The particular manner of measuring luminescence is not critical to the invention.

The following examples are offered by way of illustration and not by way of limitation.

EXAMPLES

EXAMPLE 1

Preparation and testing of PSA-Luciferase constructs

Materials and Methods

Cells and Culture Methods. LNCaP cells were obtained at passage 9 from the American Type Culture Collection (Rockville, MD). LNCaP cells were maintained in RPMI 1640 medium (RPMI) supplemented with 10% fetal bovine serum (FBS; Intergen Corp.), 100 units/mL of penicillin, and 100 units/mL streptomycin. LNCaP cells being assayed for luciferase expression were maintained in 10% strip-serum (charcoal/dextran treated fetal bovine serum to remove T3, T4, and steroids; Gemini Bioproduct, Inc., Calabasas, CA) RPMI. The cells were periodically tested for the production of PSA which was consistently above 20 ng/mL per day.

Selection for a stably integrated plasmid DNA was performed in RPMI medium containing G418 (GibcoBRL, NY). The level of G418 in RPMI was decreased from 500 to 100 µg/mL after selection of the parental LNCaP clones for evaluation; these clones were maintained in 100 µg/mL G418 at all times prior assaying. Subclones having enhanced luciferase activity were obtained from the parental cell line by the method of limited dilution cloning.

PSE-Luciferase (CN1) Plasmid Constructs. The luciferase gene from *Photinus pyralis* from the plasmid pJD206 (de Wet et al. *Molecular and Cellular Biology* (1987) 7:725-737) was excised by cleavage with restriction enzymes HindIII and BamHI, then ligated into similarly cleaved pUC18. This plasmid was then cleaved with HindIII and KpnI again to remove the luciferase fragment which was then ligated into similarly cleaved pBluescript KSI(+)(Stratagene). The resulting plasmid was designated LB78. The 5.8 kb HindIII

fragment containing the PSA gene upstream region was excised from the plasmid CN0 (Schuur et al., *J. Biol. Chem.* (1996) 271:7043-7051) and ligated to HindIII-cleaved LB78. A clone was selected with the cap site of the PSA gene in the PSA gene fragment adjacent to the beginning of the luciferase gene to drive its synthesis. The resulting clone was designated CN1 (PSE-Luc).

Transfections of LNCaP cells For transfections, LNCaP cells were plated out at a cell density of 5×10^5 cells per 6-cm culture dish (Falcon, NJ) in complete RPMI. DNAs were introduced into LNCaP cells after being complexed with a 1:1 molar lipid mixture of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP; Avanti Polar Lipids, AL) and dioleoyl-phosphatidylethanolamine (DOPE; Avanti Polar Lipids, AL). DNA/lipid complexes were prepared in serum-free RPMI at a 2:1 molar ratio. Typically, 8 μ g (24.2 nmole) of DNA was diluted into 200 μ L of incomplete RPMI and added dropwise to 50 nmole of transfecting lipids in 200 μ L of RPMI with gentle vortexing to insure homogenous mixing of components. The DNA/lipid complexes were allowed to anneal at room temperature for 15 minutes prior to their addition to LNCaP cells. Medium was removed from LNCaP cells and replaced with 1 mL of serum-free RPMI followed by the dropwise addition of DNA/lipid complexes. Cells were incubated with complexes for 4-5 hours at 37°C, 5% CO₂. Medium was removed and cells washed once with PBS. The cells were then trypsinized and resuspended in 10% strip-serum RPMI (phenol red free). Cells were replated into an opaque 96-well tissue culture plate (Falcon, NJ) at a cell density of 40,000 cells/well per 100 μ L media and assayed. Varying amounts of drugs (e.g. androgens and anti-androgens) were added 16 hours later and assayed for luciferase activity 32 hours thereafter.

Generation of a stably transfected cell line expressing luciferase was accomplished by co-transfecting the plasmid pcDNA3 with PSE-Luc. The neomycin gene of pcDNA3 confers resistance to the antibiotic G418, allowing selection of stably transfected LNCaP cells. LNCaP cells were co-transfected with PSE-Luc and pcDNA3 as described for transient transfections. Briefly, 1 μ g of pcDNA3 and 1-10 μ g of PSE-Luc were diluted into 200 μ L of RPMI and complexed with two molar equivalents of DOTAP:DOPE (1:1) in 200 μ L RPMI. Addition of DNA to lipids was dropwise with gentle vortexing to homogeneously mix the

samples. After annealing the complexes for 15 minutes, they were added dropwise to LNCaP cells in 1 mL RPMI and incubated overnight (12 hours) at 37°C. Media/DNA-lipid complexes were removed from the tissue culture plates and supplemented with complete RPMI containing 500 µg/mL G418. The selection media was kept at 500 µg/mL G418 for three weeks before being lowered to 250 µg/mL. G418 resistant colonies appeared after four weeks and were allowed to grow until visible by eye, upon which colonies were trypsinized (0.25% trypsin) and transferred to a 24 well tissue culture plate, followed by further expansion. Clones were assayed for luciferase expression after they had reached 5×10^6 cells. Screening identified the clone CN1013 which was selected for further study. A clone 5-10 fold more active than CN1013, designated CN1013.7, was obtained by subcloning the parental line once by limiting dilution.

Induction and Assaying of Transient and Stable PSE-Luc LNCaP Cells. For both transient and stably transfected LNCaP cells, a variety of androgens and anti-androgens -- methyl trienolone (R1881, DuPont NEN), dihydrotestosterone (DHT, Sigma), cyproterone acetate (CA) and hydroxyflutamide (Ho-Flu)-- were used to induce expression of the luciferase reporter gene. Androgens or anti-androgens were prepared at 3x concentrations in 10% strip-serum RPMI and added as 50 µL aliquots to each well of the 96-well plate. Cells were incubated with either androgens or anti-androgens for 48 hours before assaying. Assays were done in triplicate or quadruplicate. The concentration of dihydrotestosterone (DHT) was measured by the Testosterone ELISA Kit (Neogen Corporation). The assay has 100% cross reactivity with DHT.

In the case of stably transfected PSE-Luc/LNCaP clones, media was removed and cells washed with PBS (2 x 20 mL). The clonal cells were then maintained in 10% strip-serum RPMI (phenol red free) for 24 hours prior to trypsinizing and replating into an opaque 96-well plate - 40,000 cells/well per 100 µL media. Cells were allowed to become adherent overnight before the addition of either androgens or anti-androgens. Incubation of clonal cells in strip-serum RPMI prior to induction with drug(s) substantially lowered background luciferase expression.

The luciferase assay of both transient and stably transfected cells was performed in the same manner. After induction of cells with androgens or anti-androgens for 48 hours, media was removed and 50 μ L of lysis reagent added (0.1 M potassium phosphate buffer at pH 7.8, 1% Triton X-100, 1 mM dithiothreitol, 2mM EDTA) to each well. Cells were assayed within 5 15 minutes of lysis or stored at -80°C until analysis. Storage of cell lysates at -80°C for five days or less did not result in significant loss of luciferase activity.

The Enhanced Luciferase Assay Kit (Analytical Luminescence Laboratory, MI) was used to quantitate the extent of luciferase activity from PSE-Luc transfected LNCaP cells. A Dynatech 3000 96-well plate luminometer (Dynatech, VA) was used to measure the amount of 10 light generated from the assay. The instrument was run in the Enhanced Flash Mode, employing a dual injector system for substrate addition. Optimal assay conditions and Luminometer parameters were as follows: addition of 60 μ L of Substrate A (buffer), 1 second delay, addition of 60 μ L of Substrate B (luciferin reagent), 1 second delay, integrate signal for 3 seconds. The results are depicted as the integral sum in relative light units (RLUs). The 15 extent of induction by androgens/anti-androgens, e.g. fold induction, was determined by: *fold induction = RLUs [x nM drug]/RLUs [0 nM drug]*

CMV-Luc/LNCaP Cell Line. Transfections of the control plasmid, CMV-Luc, into LNCaP cells were done in the same fashion as for PSE-Luc. The stable cell line CN1006, containing CMV-Luc, was obtained by selection with G418. The luciferase assay was 20 performed as described above.

Results

Transient Transfections of LNCaP Cells with PSE-Luc. The effectiveness of utilizing PSE-Luc in transient transfections as a transcription screening assay for agonist/antagonist 25 type molecules was examined in LNCaP cells. This transcription assay was evaluated for its use in a 96-well format. The androgens, methyl trienolone (R1881) and dihydrotestosterone (DHT), were used to induce different degrees of luciferase expression under the control of the prostate-specific enhancer.

The inducibility of PSE-Luc by the synthetic androgen R1881 in transiently transfected LNCaP cells was determined. Cells were plated into an opaque 96-well plate at a cell density of 4×10^4 cells/well per 100 μ L, followed by 50 μ L of a 3x media solution containing either R1881 or DHT. Cells were incubated for 48 hours, lysed and assayed for luciferase expression. The extent of induction was determined by dividing the amount of luciferase expression (RLUs) at X nM hormone by the amount of expression without hormone. At 0 nM R1881, luciferase expression in transfected LNCaP cells was similar to background levels (approximately 1-5 RLUs). The addition of 1-50 nM R1881 resulted in an approximately 275 fold induction of luciferase expression (3,000-3,500 RLUs) over uninduced transfected cells. Peak levels of luciferase expression were obtained at 1 nM R1881, which closely corresponds to physiological levels of androgen. Variations in the amount of DNA-Lipid complexes used in transient transfections resulted in comparable results, however lower DNA concentrations (e.g. 1 and 2 μ g DNA) gave smaller RLU values after induction. Lastly, %CV varied ranging from 10-30%.

A second androgen, dihydrotestosterone (DHT), was evaluated for its inducibility of transiently transfected LNCaP cells. DHT is a naturally occurring human androgen and the reductive analog of testosterone. The extent of fold induction increased with increasing concentration of DHT. Peak levels of approximately 100 fold were obtained over the background value of 25 RLUs for DHT concentrations of 100 and 200 nM (e.g. 2,500-3,000 RLUs). A comparison of R1881 and DHT shows that approximately 100 fold more DHT is required relative to R1881 to obtain comparable luciferase activity. The difference in fold induction between the two androgens, e.g. 100 vs. 250 fold induction, can be explained by a 2 fold higher background signal for the DHT (12 vs. 25 RLUs), which likely resulted from the particular experimental procedures employed. However, the overall peak expression levels stimulated by the two androgens are comparable. The higher concentration of DHT required to achieve the same luciferase expression levels obtained with R1881 is addressed later.

Androgen and Anti-androgen Responsiveness of Stable Transfected PSE-Luc LNCaP Cell Line. LNCaP cells were co-transfected with PSE-Luc and pcDNA3 containing the neomycin gene. LNCaP clones containing both genes were selected with G418 and examined

for luciferase expression after induction with either androgen or anti-androgens. As in the case of transient transfections with PSE-Luc, the assay is evaluated in the 96-well format for high throughput screening (HTS) of potential agonist/antagonist.

The hormones R1881 and DHT were utilized to screen for androgen-responsive LNCaP clones containing the PSE-Luc genes. Two clones, designated CN1010 and CN1013, exhibited luciferase activity upon incubation in 1nM R1881 and were characterized further with varying concentrations of R1881 and DHT. The androgen-responsiveness profile of CN1013 is similar to that obtained for transient transfections. Peak values of R1881 induction were obtained at physiological levels (0.1 - 1 nM), while DHT required 100-200 fold greater amounts for comparable expression. The EC₅₀ of R1881 in CN1013 was 0.075nM.

The luciferase responsiveness of CN1013 to anti-androgens, hydroxyflutamide (HO-Flu) and cyproterone acetate (Cypro. A), as well as their antagonist behavior to R1881 (1 nM) induced cells was evaluated. Incubation of CN1013 with either anti-androgen resulted in luciferase expression levels similar to that obtained for R1881, but only at elevated concentrations of 100-1,000 fold higher (Figures 1A and 1B); zero or minimal expression was observed at physiological concentrations. The anti-androgens ability to inhibit luciferase expression after induction with 1 nM R1881 is also shown in Figure 1. At all anti-androgen concentrations examined, there was neither inhibition nor induction of luciferase expression after R1881 had been added. The addition of other non-steroidal intracellular receptor ligands unrelated to the androgen receptor, i.e. retinoic acid (RA), did not result in either induction or inhibition of CN1013.

The intra-assay %CVs of the stable cell line CN1013 typically varied between 5-10%. While the initial characterization of CN1013 resulted in %CV slightly higher than 10%, later experiments were able to lower the intra-assay %CV to an acceptable range (Figures 1A and 1B). Transient transfection assays yielded %CVs of 10-30%, whereas stable cell line assays (CN1013), yielded %CVs of 5-10%.

Metabolism of Dihydrotestosterone (DHT) in CN1013 Cell Line. The higher levels of DHT needed to induce luciferase expression in either CN1013 or transient transfections was investigated. The decrease of DHT concentration in CN1013 cells was measured kinetically

utilizing the Testosterone ELISA Kit by Neogen Corporation (100% cross reactivity with DHT). The metabolism of DHT occurs rapidly within 1-4 hours of addition to CN1013 cells, while the DHT concentration remained constant when unexposed to CN1013 cells. The half life of 10 nM DHT in CN1013 cells was calculated to be approximately 1.1 hours. The metabolized product was not identified.

While the overall luciferase expression levels between transient transfections and CN1013 are similar (3000-4000 RLUs), the extent of fold induction upon androgen addition is approximately 5-10 times lower in the latter case due to significant background signal (e.g. 100-200 RLUs). The larger background signal is a result of the requirement of growing CN1013 in hormone containing RPMI. Incubation of CN1013 in 10% strip-serum RPMI (minus hormone) prior to plating into 96-well plates lowered background signal moderately. Further decreases in overall luciferase expression were observed with passage number of the cell line. A comparison of the RLUs at passage 5 and 15 showed an approximate 3-5 fold decrease in luciferase expression, however the overall level of induction remained identical.

The decrease in luciferase expression of CN1013 with increasing passage number resulted in the need to select subclones having enhanced expression levels. Subclones of PSE-Luc/LNCaP were obtained from the parental cell line CN1013 by limiting dilution. Screening of these clones produced a single active clone, designated CN1013.7, which was 5-10 times more active than the parental cell line yielding 100-200 fold induction with R1881.

Luciferase Expression of CMV-Luc/LNCaP Stable Cell Line. LNCaP clones containing the CMV-Luc gene were screened for stable expression of the luciferase gene (i.e. selection of stable cell line). A 3-4 fold increase in expression levels over the uninduced cells was observed upon the addition of 10-1000 nM androgen. A similar androgen stimulation of CMV-Luc expression in transient transfection of LNCaP cells was reported by Pang et al., Hum. Gene Ther. (1995) 6:1417-1426. The slight increase in expression levels was attributed to cell proliferation resulting from increased R1881 addition.

EXAMPLE 2

Construction of reporter constructs in which expression of reporter genes is under the control of the hKLK2 5'-flanking region

To assess the function of the DNA segment containing the enhancer, a series of constructs was generated by inserting the *hKLK2* 5'-flanking region, shown schematically in Figure 2, upstream of the luciferase reporter gene. The activity of these fragments was compared with that of CN299, a plasmid with the full *hKLK2* promoter (-605 to +33) driving the expression of firefly luciferase. The constructs are as follows:

- To clone the *hKLK2* full promoter an approximately 600 bp fragment was amplified with the oligonucleotides 41.100.1 and 42.100.2 (5'-GAT CAC CCG TGC TCA CGC CTG TAA TCT CAT CAC-3' (SEQ ID NO:2). PstAI site underlined). 42.100.2 corresponds to the upstream region of the *hKLK2* promoter. The PCR product was then cloned into pGEM-T vector (Promega) to generate CN294.
- CN299 is a plasmid containing the luciferase coding segment driven by the full *hKLK2* promoter. The full promoter region was released from CN294 by NcoI-SacI digestion and ligated into a similarly cut pGL3-Basic (Promega) to generate CN299.
- CN322 is a plasmid containing the entire structural gene of firefly luciferase driven by the human *hKLK2* promoter and the other all regulatory elements. The entire 12 kbps *hKLK2* 5'-flanking region was excised from CN312 by SacII/SpeI digestion and ligated into SacII/SpeI digested pGL3-Basic to produce CN322.
- CN324 is a luciferase construct containing the *hKLK2* minimal promoter driving the luciferase coding region. The minimal *hKLK2* promoter was released from CN317 by NcoI-SacI digestion and ligated into a similarly cut pGL3-Basic to generate CN324.

- CN325 is the same as CN324, except that a XhoI site (instead of a PstI site) was created at the 5' end of the minimal promoter.
- CN355 was created by digesting CN340 with XhoI and KpnI. The released fragment (~3.8 kbps) was ligated into CN325, upstream of the minimal promoter.

EXAMPLE 3

Effects of the hKLK2 5'-flanking region

To determine the effect of the 12 kbp 5'-flanking sequence on promoter activity, two constructs were created: CN299 and CN322. The *hKLK2* promoter was cloned upstream of the *luc* gene to create CN299, as described in Example 2. The entire 12 kbp sequence upstream of the *hKLK2* gene (including the promoter) was cloned upstream of the *luc* gene to create CN322, as described in Example 2. Each construct was then used to transfect LNCaP cells. The media in half of the dishes was supplemented with 0.5 nM R1881. The cells were harvested 48 hours post transfection and the luciferase activity was measured. Figures 3A and 3B summarize the data and demonstrate that CN322 has higher activity than CN299. At both R1881 concentrations tested, CN322 had higher activity than CN299. At 0 nM, CN322 was 12 fold more active than CN299. At 0.5 nM, CN322 was approximately 36 fold more active than CN299. These data suggest that the 12 kb 5'-flanking sequence contains an enhancer and that this enhancer is also androgen responsive.

EXAMPLE 4

Characterization of the hKLK2 enhancer

The results of the previous experiment (Example 3) suggested that the luciferase activity of the putative enhancer found in CN322 responded in an androgen dependent manner. To determine if the *hKLK2* 5'-flanking sequence did indeed contain an androgen responsive element, two experiments were conducted. In the first experiment, LNCaP cells were transfected with CN322, the transformants were incubated in medium containing various concentrations of R1881, and 48 hours after transfection, luciferase activity was measured. The results are summarized in Figures 4A and 4B. In short, CN322 responded to the

testosterone analog R1881 in a concentration dependent manner. Peak induction of activity was estimated at 1 nM R1881, about 9 fold over the 0 nM activity.

In the second experiment, the effect of time of incubation in the presence of R1881 on the activity of the 12 kb 5'-flanking sequence was assessed. LNCaP cells were transfected with CN322 and incubated for various periods of time in the presence of 0.5 nM R1881 before harvesting. The results are summarized in Figure 5. The peak luciferase activity was seen at 60 hours post transfection, but the overall upward trend seemed to plateau at about 48 hours post transfection.

To summarize these two experiments, it seemed that the *hKLLK2* enhancer appears to be androgen responsive and peak induction of *luc* activity takes place somewhere between 48 and 60 hours post transfection.

EXAMPLE 5

Tissue specificity of the hKLLK2 enhancer

Knowing that the *PSA* enhancer is tissue specific, a series of experiments was conducted to determine if the same was true for the *hKLLK2* enhancer. In the first experiment, LNCaP cells (a PSA-producing prostate cancer cell line) and 293s (a human embryonic kidney cell line) were transfected with CN299 or CN322 (Example 2). Half of the dishes were supplemented with 1 nM R1881, and the cells were harvested 48 hours post transfection. The LNCaP cells transfected with CN322 exhibited a 17 fold induction of activity in the presence of 1 nM R1881 when compared to the background activity at 0 nM R1881. The 293s transfected with CN322 showed a reduction of luciferase activity in the presence of 1 nM R1881. CN299 exhibited a 2-3 fold induction in the presence of 1 nM R1881, and a reduction of activity in the 293 cells. The results of this first experiment are summarized in Figure 6. The results of this experiment again support the conclusion that the *hKLLK2* enhancer is androgen inducible.

Results of earlier experiments indicated that a putative *hKLLK2* enhancer may lie between the *Apal* site at approximately -6200 bp and the *XhoI* site at approximately -2400 bp of the *hKLLK2* enhancer. This 3.8 kbp fragment was fused upstream of the minimal *hKLLK2*

promoter and then cloned upstream of the *luc* gene, creating CN355. A variety of cell lines were transfected with CN322 or CN355 by incubating them with the complexes in complete media overnight. The complexes were then aspirated and the media was replaced with stripped serum media. The media in half of the plates was supplemented with 1 nM R1881. The cells were then harvested 48 hours after the removal of the DNA-lipid complexes and tested for luciferase activity. The results are summarized in Figure 7.

CN322 gave almost a 100 fold induction of activity in the presence of 1 nM R1881 in the LNCaP cells. CN355 exhibited a 35-fold induction of activity under the same conditions. All of the other cell lines, including the prostate-derived cell line PC3, showed little androgen inducibility. In fact, CN322 and CN355 showed only about a 1-2 fold induction in any of the other cell lines. Although the PC3 cell line is prostate derived, it lacks an androgen receptor. To further delineate the sequences required for enhancer activity, the construct CN379 was made, which has, in addition to a minimal *hKLLK2* promoter, the region from -5155 to -3412 driving expression of the luciferase gene. Using the same assay methods described above, this construct gave approximately 54-fold induction of luciferase activity in the presence of inducing agent R1881.

These data show that the minimal enhancer constructs CN355 and CN379 retained some of the activity of the full 12 kbps 5'-flanking sequence, indicating that part of the putative *hKLLK2* enhancer is between the *Apal* and *XhoI* sites previously described above. The data also support the conclusion that the *hKLLK2* enhancer is androgen responsive and that its activity is restricted to cell lines containing an androgen receptor.

It is evident from the above results that simple and rapid screening methods are provided for determining activity of compounds in inhibiting proliferation of prostate cancer. The methods employ cells which are stable, can be easily grown, and can be used in a conventional format to identify the activity of specific compounds. The results are at least semi-quantitative, and allow for high throughput screening with automated equipment.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

WO 98.05797

PCT/US97/13888

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(1) APPLICANT: HENDERSON, Daniel R.
SCHUUR, Eric R.
LAMPARSKI, Henry G.
YU, De Chao

(2) TITLE OF THE INVENTION: PROSTATE CANCER DRUG SCREENING

(3) NUMBER OF SEQUENCES: 2

(4) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: MORRISON & FOERSTER
(B) STREET: 755 PAGE HILL ROAD
(C) CITY: Palo Alto
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 94304-1018

(5) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(6) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE: 04-AUG-1997
(C) CLASSIFICATION:

(7) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:

(8) ATTORNEY/AGENT INFORMATION:

(A) NAME: Catherine, Polizzi M
(B) REGISTRATION NUMBER: 40,130
(C) REFERENCE/DOCKET NUMBER: 14302-20003.20

(9) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415-813-5600
(B) TELEFAX: 415-494-0792
(C) TELEX: 706141

(1) INFORMATION FOR SEQ ID NO:1:

(A) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2587 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(X1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

GAATTCAGAA ATAGGGGAAG GTTGAGGAAG GACACTGAAC TCAAAGGGGA TACAGTGATT      60
GGTTTATTTG TCTTCTCTTC ACAACATTGG TGCTGGAGGA ATTCCCACCC TGAGGTTATG      120
AAGATGTCTG AACACCCCAAC ACATAGCACT GGAGATATGA GTCGACAAAG AGTTTCTCAG      180
CCACAGAGAT TCACAGCCTA GGCAGGAGG ACACTGTACG CCAGGCAGAA TGACATGGGA      240
ATTGCCCTCA CGATTGGCTT TAAGAAGCAA GGACTGTGGG AGGTGGGCTT TGTAGTAACA      300
AGAGGGCAGG GTGAACCTG ATTCCTATGG GGAATGTGA TGGTCTGTG ACAAATTTTT      360
CAAGCTGGCA GGAATAAAAA TCATTACGG TGAGGACCTG TGGAGGGCGG CTGCCCCAAC      420
TGATAAAGGA AATAGCCAGG TGGGGCCCTT TCCCATTGTA GGGGGGACAT ATCTGGCAAT      480
AGAAGCCTTT GAGACCCCTT AGGGTACAAG TACTGAGGCA GCAAATAAAA TGAAATCTTA      540
TTTTTCAACT TCATACTGCA TGGGTGTGAA GATATATTTG TTTCTGTACA GGGGGGTGAGG      600
GAAAGSAGGG GAGGAGGAAA GTTCTGTGAG GTCTGGTTTG GTCTGTGAT CCAGGGGGTC      660
TTGGAACTAT TTAATTAATA TTAATTAATA ACAAGGAGT GTTTTAAAT AAATTAATTT      720
AAATTAATTT TTAATTTATT TTATCTTAAG TTCTGGGCTA CATGTGCAGG ACGTGCAGCT      780
TTGTTACATA GGTAAACGTG TGGCATGGTG GTTTGCTGTA CCTATCAACC CATCACCTAG      840
GTATTAGGCC CAGCATGCAT TAGCTGTGTT TCCTGACGCT CTCCTCTCC CTGACTCCCA      900
CAACAGGCCC CAGTGTGTGT TTTCCCCCTC CCGTGTGTCCA TGTGTTCTCA TTGTTGAGCT      960
CCCCTTATA AGTGAGAAAC TGTGTGTGTT GGTTTTCTGT TCTGTGTGTA GTTTGCTGAG      1020
GATAATGGCT TCCACCTCCA TCGATGTTCC TGCAAAGGAC GTGATCTTAT TCTTTTATAT      1080
GGTTGCATAG AAATTGTTTT TACAATCCA ATTGATATTG TATTTAATTA CAAGTTAATC      1140
TAATTAGCAT ACTAGAAGAG ATTACAGAAG ATATTAGGTA CATTGAATGA GGAATATAT      1200
AAAATAGGAC GAAGGTGAAA TATTAGGTAG GAAAAGTATA ATAGTTGAAA GAAGTAAAAA      1260
AAAATATGCA TGAGTAGCAG AATGTAAAG AGGTGAAGAA CGTAATAGTG ACTTTTTAGA      1320
CCAGATTGAA GCACAGAGAC AAAAAATTT TAAGGAATTG CTAAACCATG TGAGTGTAG      1380
AAGTACAGTC AATAACATTA AGCCTCAGG AGGAGAAAAA AATAGGAAAG GAGGAAATAT      1440
GTGAATAAAT AGTAGAGACA TTTTGTATGG ATTTTAAAT ATTTGAAAGA CCTCACATCA      1500
AAGGATTCAT ACCGTGCCAT TBAAGAGGAA GATGGAAAAA CCAAGAGGCC AGATGAAAGT      1560
TAGAAATATT ATTGGCAAAG GTTAAATGTT AAAAGTCCTA GAGAGAAAGG ATGGCAGAAA      1620
TATTGGCGGG AAAGAATGCA AACCTAGAA TATAAATTCA TCCCAACAGT TTGGTAGTGT      1680
GCAGCTGTAG CTTTTCTAG ATAATACACT ATTGTCATAC ATCGCTTAAG CGAGTGTAAA      1740
ATGGTCTCCT CTTTTATTT ATTTATATAT TTATTAGTT TTGAGATGGA GCCTCGCTCT      1800
GTCTCCTAGG CTGGAGTGCA ATAGTGCGAT ACCACTCACT GCAACCTCTG CCTCCTCTGT      1860
TCAAGTGATT TTCTTACCTC AGCCTCCCGA GTAGCTGGGA TTACAGGTGC GTGCCACCAC      1920
ACCCGGCTAA TTTTGTATT TTTGTAGAG ACGGGGTTTT GCATGTTGG CCAGGCTGGT      1980
CTTGAACCTC TGACATCAGG TGATCCACCT GCCTTGGCCT CTAAGGTGC TGGGATTACA      2040
GGCATGAGCC ACCGTGCCCA ACCTCTTTAT TTATTTTTTA TTTTATTTT TAAATTTTCA      2100
CTTCTATTTG AAATACAGGG GGCACATATA TAGGATTGTT ACATGGGTAT ATTGAATCA      2160
GGTAGTATC ATACTACCCA AAGGTAGGT TTTCAACCCA CTCCTCTCTT TTTCTCTCTC      2220
ATTCTAGTAG TGTGAGTGT CTATTGTTCT CATGTTTATG TGTATGTGTG CTCCAGGTTT      2280
AGCTCCCAAC TTTAAGTGAG AACGTGTGGT ATTTGATTTT CTGTCCCTGT GTTAATTCAC      2340
TTAGGATTAT GGTTCACAGC TCATTTCATA TTCTGTAAA GATATGATT CATTTTTTCA      2400
GGCCATGCGG TATTCCATAT TGGTATAGA TCACATTTTC TTTCTTTTTT TTTTGTGAGA      2460
CGGAGTCTTG CTTTGTGCCC TAGGCTGGAG TGCAGTAGCA CATCTCGGC TCACTGCAAG      2520
CTTCACCTCC GGGGTTACAG TCATTCTTCT GTCTCAGCTT CCAAGTAGC TGGGACTACA      2580

```

GGCGCCCGCC	ACCACGTCGG	GCTAATTTTT	TTGTGTGTTT	TTAGTAGAGA	TGGGGGTTTT	2640
ACTGTGTAG	CCAGGATGGT	CTTGATCTCC	TSACCTTGTT	GTCCACCTGC	CTCGGTCTCC	2700
CAAAGTGCTG	GGATTACAGG	GGTGAGCCAC	TGCGCCCGGC	CCATATATAC	CACATTTTCT	2760
TTAACCAATC	CACCATTGAT	GGGCAACTAG	GTAGATTCCA	TGATTCCAC	AGTTTTGCTA	2820
TGTGTGCAG	TGTGGCAGTA	GACATATGAA	TGAATGTSTC	TTTTTGSTAT	AATGATTTGC	2880
ATTCCTTTGG	GTATACAGTC	ATTAATAGGA	GTGCTGGGTT	GAACGGTGCC	TCTGTTTTAA	2940
ATTCTTTGAG	AAITTTCCAA	ACTGTTTGCC	ATAGAGAGCA	AACTAATTTA	CATTTCCACG	3000
AACAGTATAT	AAGCAITCCC	TTTTCTCCAC	AGCTTTGTCA	TCATGTTTTT	TTTTTTTCTT	3060
TATTTTAAAA	AAGAATATGT	TGTTGTTTTT	CCAGGGTACA	TGTGCAGGAT	GTGCAGGTTT	3120
GTTACATAGG	TAGTAAACGT	GAGCCATGGT	GGTTTGCTGC	ACCTGTCAAC	CCATTACCTG	3180
GGTATGAAGC	CCTGCCTGCA	TTAGCTCTTT	TCCCTAATGC	TCTCACTACT	GCCTCCACCT	3240
CACCTGACAC	GGGCAACACG	ACAACCTACA	GAATGGGAGG	AAATTTTTGC	AATCTATTCA	3300
TCTGACAAAG	GTCAAGAATA	TCCAGAATCT	ACAAGGAAC	TAAGCAAAAT	TTTACTTTTT	3360
AATAATAGCC	ACTCTGACTG	CGGTGAAATG	GTATCTCATT	GTGGTTTTCA	TTTGAATTTT	3420
TCTGATGATC	AGTGACGATG	AGCATTTTTT	CATATTGTTT	GGTGTCTTGT	ACGTCTTTTT	3480
AGAAGTGTCT	CTTCAIGCCT	TTTGGCCACT	TTAATGGGAT	TATTTTTTGC	TTTTTAGTTT	3540
AAGTTTCCTTA	TAGATTCTGG	ATATTAGACT	TCTTATTGGA	TGCATAGTTT	GTGAATACTC	3600
TCTTCCATTG	TGTAGGTTGT	CTGTTTACTC	TATTGATGGC	TTCTTTTGCT	GTGCCGAAGC	3660
ATCTTAGTTT	AATTAGAAAC	CACCTGCCAA	TTTTTGTTTT	TGTTGCAATT	GCTTTTGGGG	3720
ACTTAGTCAT	AACTCTTTG	CCAAGGTCTG	GGTCAAGAAG	AGTATTTCCT	AGGTTTTCTT	3780
CTAGAATTTT	GAAGTCTGA	ATGTAACAT	TTGCATTTTT	AATGCATCTT	GAGTTAGTTT	3840
TTGTATATGT	GAAGGTCTA	CTCTCATTTT	CTTCCCTCT	TTCTTTCTTT	CTTTCTTTTT	3900
TTTCTTTCTT	TTTCTTTCT	TTTCTTTCTT	TTTCTTTCT	TTTCTTTCT	TTTCTTTCT	3960
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4020
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4080
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4140
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4200
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4260
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4320
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4380
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4440
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4500
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4560
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4620
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4680
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4740
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4800
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4860
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4920
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	4980
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5040
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5100
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5160
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5220
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5280
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5340
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5400
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5460
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5520
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5580
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5640
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5700
TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	TTTCTTTCTT	5760

TTGTCTGSCCT	GCCACCTGAG	ACACGGACAT	GGCTTCTGTT	GGTAAGTCTC	TATTAATGT	5820
TTCTTTCTAA	GAAACTGGAT	TTCTCAGCTT	GTTCCTTTGG	CCCTCAGCT	TCCTCAGACT	5880
TTGGGGTAGG	TTGCACAACC	CTSCCCACCA	CGAAACAAAT	GTTTAATATG	ATAAATATGG	5940
ATAGATATAA	TCCACATAAA	TAAAACTCT	TGSAGGGCCC	TCAATAATTG	TTAAGAGTGT	6000
AAATGTGTCC	AAAGATGGAA	AATGTTTGAG	AACACTGTCT	CCAGAGATTT	TCCTGAGTTC	6060
TAGAGTGTGG	GAATATAGAA	CTTGAGAGCTT	GGCTTCTTCA	GCCTAGAAATC	AGGAGTATGG	6120
GGCTGAAGTC	TGAAGCTTGG	CTTCAGCAGT	TTGGGGTTGG	CTTCCGGAGC	ACATATTTGA	6180
CATGTTGCCA	CTGTGATTTG	GGCTTTGGTA	TTTGTCTCTG	ATCCTAATGT	CTGTCCCTGA	6240
GGCATCTAGA	ATCTGAATTC	TTTGGTCAGA	ATTCTATTAT	CTTGAGTAGG	ACATCTCCAG	6300
TCCTGCTTCT	GCCTTCTAGG	CTTGGAGTCT	GTAGTCAGTG	ACCCGGTCTG	GCATTTCAC	6360
TTCATATACA	GTGGGCTATC	TTTTGGTCCA	TGTTTCAACC	AAACAACCGA	ATAAACCCATT	6420
AGAACCCTTC	CCCCTTCTCC	TAGCTGCAAT	GTTAAACCTA	GGATTTCTGT	TTAATAGGTT	6480
CATATGAATA	ATTTGAGCCT	TATCCAACTT	TACATTCTCT	CTACCGTTAT	TCTACACCCA	6540
CTTTAAAAAT	GCATTCCCAA	TATATTCCTT	GGATTCTACC	TATATATGGT	AATCCTGGCT	6600
TTGCCAGTTT	CTAGTGCAAT	AACATACCTG	ATTACATTC	TTTACTTTA	AAGTGGAAAT	6660
AAGAGTCCCT	CTGCAGAGTT	CAGGAGTTCT	CAAGATGGCC	CTTACTTCTG	ACATCAATTG	6720
AGATTTCAAG	GGAGTGGCCA	AGATCATCCT	CAGGTTCACT	GATTGCTGGT	AGCCCTCATA	6780
TAACCTCAATG	AAAGCTGTTA	TGCTCATGGC	TATGGTTTAT	TACAGCAAAA	GAATAGAGAT	6840
GAAAACTAG	CAAGGGAAGA	GTTCATGGG	GCAAGACAA	GGAGAGCTCC	AAGTGCAGAG	6900
ATTCCTGTTG	TTTTCTCCCA	GTGGTGTCT	GGAAAGCAGT	ATCTTCTCCA	TACATGATG	6960
TGTGATAATA	TTCAGTGTAT	TGCCAATCAG	GGAACTCAAC	TGAGCCTTGA	TTATATTGGA	7020
CTTTGGTTGC	ACAGACATGT	CGACCACTTT	CATGGCTGAA	CTTTAGTACT	TAGCCCTCC	7080
AGACGTCTAC	AGCTGATAGG	CTGTAACCCA	ACATTGTCTC	CATAAATCAC	ATTGTTAGAC	7140
TATCCAGTGT	GGCCCAAGCT	CTCGTGTAAA	CACAGGCAC	CTAAACAGGC	AGGATATTTT	7200
AAAAGCTTAG	AGATGACCTC	CTAGGAGCTG	AATGCCAAGA	CCTGGCCTCT	TTGGGCAAGG	7260
AGAATCCTTT	ACCGCACACT	CTCCTTCACA	GGTTTATGT	GAGGATCAAA	TGTGGTCATG	7320
TGTGTGAGAC	ACCAGCACAT	CTCTGGCTGT	GGAGAGTGAC	TTCTATGTGT	GCTAACATTG	7380
CTGAGTGCTA	AGAAAGTATT	AGCATGGCT	TTGAGCCTC	ACAGATGCTC	ATCTAATCCT	7440
CACAACATGG	CTACAGGGTG	CTCACTACTA	GCCTCATTTG	ACAGAGGAAA	GGACTGTGGA	7500
TAAGAAGGGG	GTGACCAATA	CTTCAGAGTC	ATTCTGGATG	CAAGGGGCTC	CAGAGGACCA	7560
TGATTAGACA	TTGTCTGCAG	AGAAATTATG	CTGGATGTCT	TCTGCCCCGG	AAAGGGGGAT	7620
GCCTTTCTCT	TGACCCCTTA	CTTCAGATCT	TGACTTTGAG	GTTATCTCAG	ACTTCTCTTA	7680
TGATACCAGG	AGCCCATCAT	AATCTCTCTG	TGCTCTCTCC	CCTTCTCTCAG	TCTTACTGCC	7740
CACTCTTCCC	AGCTCCATCT	CTAGCTGGCC	AGGTGTAGCC	ACAGTACCTA	ACTCTTTGCA	7800
GAGAACTATA	AATGTGTATC	CTACAGGGGA	GAAGAAAAAA	AAGAACTCTG	AAAGAGCTGA	7860
CATTTTACCG	ACTTGCAAC	ACATAAGCTA	ACCTGCCAGT	TTTGTGCTGG	TAGAATCAT	7920
GAGACTCTTG	GGTCAGAGGT	AAAAGATTTT	ATTACCCACA	GCTAAGGAGG	CAGCATGAAC	7980
TTTGTGTTCA	CATTTGTTCA	CTTTGCCCCC	CAATTCTAT	GGGATGATCA	GAGCAGTTCA	8040
GGTGGATGGA	CACAGGGGTT	TGTGGCAAG	GTGAGCAACC	TAGGCTTAGA	AATCCTCAAT	8100
CTTATAAGAA	GGTACTAGCA	AACCTTGTTCA	GTCTTTGTAT	CTGACGGAGA	TATTATCTTT	8160
ATAATTGGGT	TGAAGCAGA	CTTACTCTGG	AGGAACATAT	TGTATTTATT	GTCCTGAACA	8220
GTAAACAAAT	CTGCTGTAAA	ATAGACGTTA	ACTTTATTAT	CTAAGGCAGT	AAGCAACCT	8280
AGATCTGAAG	GCGATACCAT	CTTGCAAGGC	TATCTGCTGT	ACAAATATGC	TTGAAAAGAT	8340
GGTCCAGAAA	AGAAAACGGT	ATTATTGCCCT	TTGCTCAGAA	GACACACAGA	AACATAAGAG	8400
AACCATGGAA	AATTGTCTCC	CAACACTGTT	CACCCAGAGC	CTTCCACTCT	TGTCTGCAGG	8460
ACAGTCTTAA	CATCCCATCA	TAGTGTGTC	TACCATATCT	GGCTTCACCG	TGCCTAACCA	8520
AGATTTCTAG	GTCCAGTTCC	CTACCATGTT	TGTCAGTGCC	CCACTGCCAA	CCCCAGAATA	8580
AGGGAGTGCT	CAGAATTCCC	AGGGGACATG	GGTGGGGATC	AGAACTTCTG	GGCTTGAGTG	8640
CAGAGGGGGC	CCATACTCCT	TGTTTCCGAA	GGAGGAAGAG	GCTGGAGGTG	AATGTCTTTG	8700
GAGGGGAGGA	ATGTGGGTTT	TAACTCTTAA	AATCCCCAAG	GGAGGAGACT	GGTAAGGTCT	8760
CAGCTTCCGA	GGTACTGAGC	TGGGAATGGC	CTGAGAGGTC	TAAGAATCCC	GTATCCTCGG	8820
GAAGGAGGGG	CTGAAATTGT	GAAGGGTTGA	GTTGCAGGGG	TTTGTTAGCT	TGAGACTCCT	8880
TGGTGGGTTCC	CTGGGAAGCA	AGGACTGGAA	CCATTGGGCT	CAGGGTTTGG	TGTGAAGGTA	8940

ATGGGATCTC	CTGATTCTCA	AAGGGTCAGA	GGACTGAGAG	TTGCCCATGC	TTTGATCTTT	9000
CCATCTACTC	CTTACTCCAC	TTGAGGGTAA	TCACCTACTC	TTCTAGTTCC	ACAAGAGTGC	9060
GCCTGCGCGA	GTATAATCTG	CACATGTGCC	ATGTCCCGAG	GCCTGGGGCA	TCATCCACTC	9120
ATCATTCAGC	ATCTGCGCTA	TGCGGCGGAG	GCGGCGCGCA	TGACGTGATC	TAGCTGCCAG	9180
TATCCCTGCA	GCGCGCCTCT	CCCTTCACGT	CCCAACCATG	GAGCTGTGGA	CGTGCGTCCC	9240
CTGGTGGATG	TGGCCTGCGT	GGTCCACGGC	CGGGGCCTGG	TGTCCGATAA	AGATCCCTAGA	9300
ACCACAGGAA	ACCAGGACTG	AAAGGTGCTA	GAGAATGGCC	ATATGTGCGT	GTCCATGAAA	9360
TCTCAAGGAC	TTCTGGGTGG	AGGGCACAGG	AGCCTGAAC	TACGGGTTTG	CCCCAGTCCA	9420
CTGTCCCTCC	AAGTGAGTCT	CCGAGATACG	AGGCACTGTG	CCAGCATCAG	CTTCATCTGT	9480
ACCACATCTT	GTAACAGGGA	CTACCCAGGA	CCCTGATGAA	CACCATGGTG	TGTGCAGGAA	9540
GAGGGGGTGA	AGGCATGGAC	TCTGTGTGG	TCAGAGCCCA	GAGGGGGCCA	TGACGGGTGG	9600
GGAGGAGGCT	GTGGACTGGC	TGAGAAAGTG	GGATGTGGTT	GTGTTTGATT	TCCTTTGGCC	9660
AGATAAAGTG	CTGGATATAG	CATTGAAAAC	GGAGTATGAA	GACCAAGTTAG	AATGGAGGGT	9720
CAGGTTGGAG	TTGAGTTACA	GATGGGGTAA	AATCTGCTT	CGGATGAGTT	TGGGGATTGG	9780
CAATCTAAAG	GTGGTTTGGG	ATGGCATGCG	TTTGGGATGG	AAATAGGTTT	GTTTTTATGT	9840
TGGCTGGGAA	GGGTGTGGGG	ATTGAATTGG	GGATGAAGTA	GTTTATAGTT	TGGAGATAGA	9900
ATACATGGAG	CTGGCTATTG	CATGCCAGGA	TGTGCATTAG	TTTGGTTTGA	TCCTTAAATA	9960
AAGGAGGCTA	TTAGGTTTGT	CTTGAATTAG	ATTAAGTTGT	GTGGGTTTGA	TGGGTTGGGC	10020
TTGTGGGTGA	TGTGGTTTGA	TTGGGCTGTG	TTAAATTGGT	TTGGGTCAGG	TTTTGGTTGA	10080
GGTTATCATG	GGGATGAGGA	TATGCTTGGG	ACATGGATTG	AGGTGGTTCT	CATTCAAGCT	10140
GAGGCAAAAT	TCCTTTCAGA	CGCTCATTC	AGGGAACGAG	TGGTTTGTGT	GSGGAAATCA	10200
GGCCACTGGC	TGTGAATAAT	CTCTATCTCT	GGTCTTGAAT	TGTGATTATC	TATGTCCATT	10260
CTGTCTCTCT	CACGTGACTT	GGAAATTGATC	TGCTCATTC	GCTGGAAATG	GSGGAAGATT	10320
TTGTCAAATT	CTTGAGACAC	AGCTGGGTCT	GGATCAGCGT	AAGCCTTCCT	TCTGTTTTTA	10380
TTGAACAGAT	GAATTCACAT	TTTTTTTTTC	AAAATCAGAG	AAATCTTATA	GAGTTAACAG	10440
TGGACTCTTA	TAATAAGAGT	TACACCCAGG	ACTCTTATTC	TTGATTCTTT	TCTGAGACAC	10500
CAAAATGAGA	TTTCTCAATG	CCACCCTAAT	TCTTTTTTTT	TTTTTTTTTT	TTTTTGAGAC	10560
ACAGTCTGGG	TCTTTTGCTC	TGTCACTCAG	GCTGGAGCGC	AGTGGTGIGA	TCATAGCTCA	10620
CTGAACCCCT	GACCTCCTGG	ACTTAAGGGA	TCTCTCTGCT	TCAGCCTCCT	GAGTAGATGG	10680
GGCTACAGGT	CGTTGCCACC	ACACCTGGCT	AATTAATTTT	TTTTTTTTTT	TTTGTAGAGA	10740
AAGGGTCTCA	CTTTGTTGCC	CTGGCTGATC	TTGAACCTCT	GACTTCAAGT	GATTCTTCAG	10800
CCTTGGACTC	CCAAAGCACT	GGGATTGCTG	GCATGAGCCA	CTCACCGTGC	CTGGCTTGCA	10860
GCTTAATCTT	GGAGTGTATA	AACCTGGCTC	CTGATAGCTA	GACATTTTCA	TGAGAAGGAG	10920
GCATTGGATT	TTGCATGAGG	ACAATTCTGA	CCTAGGAGGG	CAGGTCAACA	GGAATCCCCG	10980
CTGTACCTGT	ACGTTGTACA	GGCATGGAGA	ATGAGGAGTG	AGGAGGCCGT	ACCGGAACCC	11040
CATATTGTTT	AGTGGACATT	GGATTTTGAA	ATAATAGGGA	ACTTGGTCTG	GGAGAGTCAT	11100
ATTTCTGGAT	TGGACAATAT	GTGGTATCAC	AAGGTTTTAT	GATGAGGGAG	AAATGTATGT	11160
GGGGAACCAT	TTTCTGAGTG	TGGAAGTGCA	AGAATCAGAG	AGTAGCTGAA	TSCCAACGCT	11220
TCTATTTCAG	GAACATGGTA	AGTTGGAGGT	CCAGCTCTCG	GGCTCAGACG	GATATAGGGA	11280
CCAGGAAGTC	TCACAATCCG	ATCATTTCTGA	TATTTCAGGG	CATATTAGGT	TGGGGTGCA	11340
AAGGAAGTAC	TTGGGACTTA	GGCATGAGAG	ACTTTGTATT	GAATTAATCA	GATTGGGGCT	11400
GGCCGTGGTG	CTCACGCGTG	TAATCTCATC	ACTTTGGGAG	ACCGAAGTGG	GAGGATGGCT	11460
TGATCTCAAG	AGTTGGACAC	CAGCCTAGGC	AACATGGCCA	GACCTCTCT	CTACAAAAAA	11520
ATTAAAAATT	AGCTGGATGT	GGTGGTGAT	GCTTGTGGTC	TCAGCTATCC	TGGAGGCTGA	11580
GACAGGAGAA	TCGGTTGAGT	CTGGGAGTTC	AAGGCTACAG	GGAGCTGCGA	TCACGCCGCT	11640
GCACTCCAGC	CTGGGAAACA	GAGTGAGACT	GTCTCAGAA	TTTTTTAAAA	AAGAATCAAT	11700
GATCATCCCA	ACCCCTGTTG	CTGTTTATCC	TGAGCCTGCG	TTCTCTGGCT	TTTTPCCCTA	11760
GATCATCTCT	CCATGATCCA	TAGGCTGTC	CCATCTGAG	CTCACACCGT	GGAATGCGCT	11820
CCAGACTGAT	CTAGTATGTG	TGGAACAGCA	AGTCTGGGCT	CTCCCTCCCG	TTCCACAGCT	11880
CTGGGTGTGG	GAGGGGGTTG	TCCAGCCTCC	AGCAGCATGG	GGAGGCGCTT	GCTCAGCATC	11940
TAGGTGCCAA	CAGGGCAAGG	GCGGGGTCTT	GGAGAATGAA	GGTTTTATAG	GCTCCTCAG	12000
GGAGGCCCCC	CAGCCCCAAA	CTGCACACCC	TGGCGGTGGA	CACCGGT		12047

WO 98/05797

PCT/US97/13888

(2) INFORMATION FOR SEQ ID NO:2:

(A) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(E) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GATCACCGGT GTCACGCCT TATCTCAT CAC

33

CLAIMS

What is claimed is:

1. A method for screening drugs for the treatment of prostate cancer employing PSA
5 expressing cells comprising an expression construct which comprises a transcriptional
initiation region of the prostate specific antigen enhancer and a promoter and a gene whose
expression product provides a detectable signal, wherein said gene is under the transcriptional
control of said transcriptional initiation region, said method comprising:

10 combining said PSA expressing cells with a candidate drug in the presence of an
androgen for sufficient time for detectable expression of said gene; and

detecting the level of expression of said gene as compared to the level of expression in
the absence of said candidate drug.

15 2. A method according to Claim 1, wherein said gene expresses an enzyme.

3. A method according to Claim 2, wherein said enzyme is luciferase.

4. A method according to Claim 3, wherein said detecting comprises:

20 lysing said PSA expressing cells; and

assaying said lysate for luminescence.

5. A method according to Claim 1, wherein said androgen is methyl trienolone or
dihydrotestosterone.

25 6. A method for screening drugs for the treatment of prostate cancer employing PSA
expressing cells comprising an expression construct which comprises a transcriptional
initiation region of the prostate specific antigen enhancer and a promoter and a gene encoding
an enzyme which catalyzes a reaction resulting in a detectable signal, wherein said gene is
under the transcriptional control of said transcriptional initiation region, said method
30 comprising:

combining said PSA expressing cells with a candidate drug in the presence of methyl
trienolone or dihydrotestosterone for sufficient time for detectable expression of said enzyme;

lysing said PSA expressing cells to provide a lysate and adding the substrate of said
enzyme to said lysate; and

5 detecting the level of expression of said enzyme as compared to the level of expression
in the absence of said candidate drug.

7. A method according to Claim 6, wherein said PSA expressing cells are LNCaP
cells and said enzyme is luciferase.

10 8. A method for screening compounds for the treatment of prostate cancer employing
mammalian cells comprising an expression construct, said expression construct comprising an
enhancer of a prostate-specific gene and a promoter and a reporter gene whose expression
product provides a detectable signal, wherein said reporter gene is under the transcriptional
15 control of said enhancer, said method comprising the steps of:

a) combining said cells with a candidate compound for a sufficient time for detectable
expression of said reporter gene; and

b) detecting the level of expression of said reporter gene as compared to the level of
expression in the absence of said candidate compound.

20 9. A method according to claim 8, wherein said reporter gene expresses an
enzyme.

10. A method according to claim 9, wherein said enzyme is luciferase.

25 11. A method according to claim 10, wherein said detecting comprises:
lysing said mammalian cells; and assaying said lysate for luminescence.

30 12. A method according to claim 8, wherein said enhancer is an enhancer region of
the human prostate specific antigen gene.

13. A method according to claim 8, wherein said enhancer is an enhancer region of the human glandular kallikrein (*hKCLK2*) gene.

5 14. The method according to claim 13, wherein the *hKCLK2* enhancer encompasses nucleotides 1 to 9765 of SEQ ID NO:1 or active fragments thereof.

15. The method according to claim 13, wherein the *hKCLK2* enhancer encompasses nucleotides 5976 to 9620 of SEQ ID NO:1 or active fragments thereof.

10 16. The method according to claim 13, wherein the *hKCLK2* enhancer encompasses nucleotides 6859 to 8627 of SEQ ID NO:1 or active fragments thereof.

15 17. The method according to claim 13, wherein the mammalian cells are prostate cells containing an endogenous androgen receptor.

18. The method according to claim 13, wherein the enhancer is an *hKCLK2* enhancer and the promoter is an *hKCLK2* promoter.

AMENDED CLAIMS

[received by the International Bureau on 14 March 1998 (14.03.98);
original claims 8-18 amended; new claims 19-25 added; remaining claims unchanged (3 pages)]

combining said PSA expressing cells with a candidate drug in the presence of
methyl trienolone or dihydrotestosterone for sufficient time for detectable expression of
said enzyme;

5 lysing said PSA expressing cells to provide a lysate and adding the substrate of said
enzyme to said lysate; and

detecting the level of expression of said enzyme as compared to the level of
expression in the absence of said candidate drug.

10 7. A method according to Claim 6, wherein said PSA expressing cells are
LNCaP cells and said enzyme is luciferase.

15 8. A method according to claims 1 or 6, wherein the prostate specific antigen
enhancer comprises a sequence encompassing nucleotides between about -5824 to about -
3738 of the upstream region of the PSA gene, wherein the enhancer exhibits enhancer
activity.

20 9. A method according to claims 1 or 6, wherein the prostate specific antigen
enhancer is contained within a polynucleotide fragment of about 5.8 kilobases from about -
5824 to about -1 of the upstream region of the PSA gene, wherein the enhancer exhibits
enhancer activity.

10. A method according to claim 10, wherein the promoter comprises a sequence
encompassing nucleotides between about -560 to about +7 of the PSA gene.

25 11. A method for screening compounds for the treatment of prostate cancer
employing cells comprising an expression construct, said expression construct comprising
an enhancer of a prostate-specific gene and a promoter and a reporter gene whose
expression product provides a detectable signal, wherein said reporter gene is under the
transcriptional control of said enhancer, said method comprising the steps of:

30 a) combining said cells with a candidate compound for a sufficient time for
detectable expression of said reporter gene; and

b) detecting the level of expression of said reporter gene as compared to the level
of expression in the absence of said candidate compound.

12. A method according to claim 11, wherein said reporter gene expresses an enzyme.

13. A method according to claim 12, wherein said enzyme is luciferase.

14. A method according to claim 13, wherein said detecting comprises: lysing said cells; and assaying said lysate for luminescence.

15. A method according to claim 11, wherein said enhancer is an enhancer region of the human prostate specific antigen (PSA) gene.

16. A method according to claim 15, wherein the prostate specific antigen enhancer comprises a sequence encompassing nucleotides between about -5824 to about -3738 of the upstream region of the PSA gene, wherein the enhancer exhibits enhancer activity.

17. A method according to claim 11, wherein said enhancer from the human glandular kallikrein (*hKLK2*) gene.

18. A method according to claim 17, wherein the *hKLK2* enhancer comprises a sequence encompassing nucleotides about 1 to about 9765 of SEQ ID NO:1 or active fragments thereof.

19. A method according to claim 17, wherein the *hKLK2* enhancer comprises a sequence encompassing nucleotides about 5976 to about 9620 of SEQ ID NO:1 or active fragments thereof.

20. A method according to claim 17, wherein the *hKLK2* enhancer comprises a sequence encompassing nucleotides about 6859 to about 8627 of SEQ ID NO:1 or active fragments thereof.

21. A method of any of claims 17 to 20, wherein the promoter is an *hKLK2* promoter.

22. A method of any of claims 11 to 21, wherein the cells are mammalian.

23. A method of claim 22, wherein the mammalian cells express prostate specific antigen.

5 24. A method of claim 22 or 23, wherein the cells are prostate.

25. A method of claim 24, wherein the prostate cells contain an endogenous androgen receptor.

1/7




Figure 1 A




Figure 1 B




Figure 2

3/7




Figure 3 A




Figure 3 B

4/7




Figure 4 A




Figure 4 B




Figure 5




Figure 6




Figure 7

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 97/13283

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C1201/68 G01N33/574

According to International Patent Classification (IPC), to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched: classification system followed by classification symbols:
IPC 6 C120

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

E. Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCHUUR E. ET AL: "Prostate -specific antigen expression is regulated by an upstream enhancer." JOURNAL OF BIOLOGICAL CHEMISTRY (MICROFILMS). vol. 271, no. 12, March 1996, MD US. pages 7043-7051, XP002050776 see the whole document specially see page 7044, right-hand column, last paragraph: figure 1 --- -/-	1-12

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex

Special categories of cited documents

- A. document defining the general state of the art which is not considered to be of particular relevance
- B. earlier document but published on or after the international filing date
- C. document which may throw doubts on priority claim(s) or which is cited to establish the actual date of another citation or other special reason (as specified)
- D. document referring to an oral disclosure, use, exhibition or other means
- E. document published prior to the international filing date but later than the priority date claimed
- F. later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- G. document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- H. document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- I. document member of the same patent family

Date of the actual completion of the international search

19 December 1997

Date of mailing of the international search report

15/01/1998

Name and mailing address of the ISA

European Patent Office - P.O. Box 5518 Patentplan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2240 Fax: 31 651 400 01
Fax: (+31-70) 340-3316

Authorized officer

Molina Galan, E

INTERNATIONAL SEARCH REPORT

International Application No.

PCT US 97/13888

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Date of document with indication where appropriate of the date of publication

Relevant to claim No.

- | | | |
|---|---|-------|
| Y | MURTHA P ET AL: ANDROGEN INDUCTION OF A HUMAN PROSTATE-SPECIFIC KALLIKREIN HYLK2 CHARACTERIZATION OF AN ANDROGEN RESPONSE ELEMENT IN THE 5' PROMOTER REGION OF THE GENE." BIOCHEMISTRY 32 (25), 1993, 6459-6464. CODEN: BICHAW ISSN: 0006-2960. XP002050777 cited in the application see the whole document | 13-18 |
| Y | WO 95 06754 A (UNIV CALIFORNIA) 9 March 1995 see the whole document | 1-18 |
| A | WO 95 19434 A (CALYDON INC) 20 July 1995 | |
| A | WILLIAMS T M ET AL: "ADVANTAGES OF TREFLY LUCIFERASE AS A REPORTER GENE: APPLICATION TO THE INTERLEUKIN-2 GENE PROMOTER" ANALYTICAL BIOCHEMISTRY, vol. 176, no. 1, January 1989, pages 23-32. XP000601607 | |
| A | YOUNG ET AL.: "Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein" BIOCHEMISTRY, vol. 31, 1992, EASTON, PA US, pages 818-824. XP002050778 cited in the application | |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.
PCT/US 97/13888

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9506754 A	02-03-95	AU 632398 B	02-10-97
		AU 7719094 A	22-03-95
		CA 2169466 A	09-03-95
		EP 0724648 A	07-08-96
		JP 9502345 T	11-03-97
		NO 960715 A	22-02-96
WO 9519434 A	20-07-95	AU 1686995 A	01-08-95
		CA 2181073 A	20-07-95
		EP 0755443 A	29-01-97
		JP 9509049 T	16-09-97
		US 5648478 A	15-07-97